These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2220 related items for PubMed ID: 22789766

  • 21. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J, Kang J, Lee SH, Wang C, Zhou X, Crawford J, Jacques L, Stone S.
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [Abstract] [Full Text] [Related]

  • 22. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R, Norris V, Siederer S.
    Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
    [Abstract] [Full Text] [Related]

  • 23. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R, Allen A, Bareille P, Hamilton M, Cheesbrough A.
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):2-11. PubMed ID: 27127998
    [Abstract] [Full Text] [Related]

  • 24. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium.
    Pepin JL, Cockcroft JR, Midwinter D, Sharma S, Rubin DB, Andreas S.
    Chest; 2014 Dec; 146(6):1521-1530. PubMed ID: 25058845
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA.
    Ther Adv Respir Dis; 2020 Dec; 14():1753466620963021. PubMed ID: 33121372
    [No Abstract] [Full Text] [Related]

  • 26. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG, Prosser TR.
    Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
    [Abstract] [Full Text] [Related]

  • 27. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
    Chen X, Zheng X, Jiang J, Hu P, Wu K, Zhuang L, Liu L, Du X, Kempsford R, Allen A.
    Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
    [Abstract] [Full Text] [Related]

  • 28. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun; 14():2849-2861. PubMed ID: 31839705
    [Abstract] [Full Text] [Related]

  • 29. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA.
    Respir Res; 2018 Jan 25; 19(1):19. PubMed ID: 29370819
    [Abstract] [Full Text] [Related]

  • 30. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I, Williams M, Power S, Pilcher J, Weatherall M, Baines A, Moynihan J, Kempsford R, Beasley R, FF/VI Study Team.
    Respir Med; 2016 Oct 25; 119():115-121. PubMed ID: 27692131
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
    Lin J, Tang H, Chen P, Wang H, Kim MK, Crawford J, Jacques L, Stone S.
    Allergy Asthma Proc; 2016 Jul 25; 37(4):302-10. PubMed ID: 27401316
    [Abstract] [Full Text] [Related]

  • 32. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A.
    Thorax; 2012 Jan 25; 67(1):35-41. PubMed ID: 21828231
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
    Zheng J, de Guia T, Wang-Jairaj J, Newlands AH, Wang C, Crim C, Zhong N.
    Curr Med Res Opin; 2015 Jun 25; 31(6):1191-200. PubMed ID: 25830381
    [Abstract] [Full Text] [Related]

  • 34. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
    Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, Lettis S, Barnhart F, Haumann B.
    Chest; 2012 Jul 25; 142(1):119-127. PubMed ID: 22241764
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun 25; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 36. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing.
    Kempsford RD, Oliver A, Bal J, Tombs L, Quinn D.
    Respir Med; 2013 Dec 25; 107(12):1873-80. PubMed ID: 24200619
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
    Covelli H, Pek B, Schenkenberger I, Scott-Wilson C, Emmett A, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2016 Dec 25; 11():1-12. PubMed ID: 26730183
    [Abstract] [Full Text] [Related]

  • 38. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D, Andersen L, Forth R, Jacques L, Yates L.
    J Asthma; 2018 Sep 25; 55(9):984-993. PubMed ID: 28961020
    [Abstract] [Full Text] [Related]

  • 39. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
    Sliwka A, Jankowski M, Gross-Sondej I, Storman M, Nowobilski R, Bala MM.
    Cochrane Database Syst Rev; 2018 Aug 24; 8(8):CD012355. PubMed ID: 30141826
    [Abstract] [Full Text] [Related]

  • 40. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM, Donald AC, O'Dell D, Church A, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2016 Aug 24; 11():971-9. PubMed ID: 27274218
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 111.